News Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
64.78 ^USD	+3.76%		+36.70%	+503.73%

16/04	JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target	MT
10/04	Sector Update: Health Care Stocks Slipping Late Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target	16/04	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	11/04	MT
Sector Update: Health Care	11/04	MT
Janux Therapeutics Said to be Considering Sale	10/04	MT
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports	10/04	MT
BTIG Starts Janux Therapeutics With Buy Rating, $62 Price Target	21/03	MT
Cantor Fitzgerald Starts Janux Therapeutics With Overweight Rating, $100 Price Target	20/03	MT
H.C. Wainwright Adjusts Price Target on Janux Therapeutics to $50 From $35, Keeps Buy Rating	11/03	MT
Janux Therapeutics Q4 Net Loss Narrows, Revenue Decreases	09/03	MT
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	09/03	CI
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	09/03	CI
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	09/03	BU
Janux Therapeutics Prices $296.5 Million Offering of Common Stock, Pre-Funded Warrants	29/02	MT
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants	29/02	BU
Janux Therapeutics Announces Proposed Public Offering of Common Stock	28/02	BU
Sector Update: Health Care Stocks Ease Late Afternoon	28/02	MT
Sector Update: Health Care	28/02	MT
Top Midday Gainers	28/02	MT
Janux Therapeutics Shares Soar After Wedbush Boosts Price Target Following 'Positive' Data From Two Cancer Studies	27/02	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Key Data for Rate-Cut Hints	27/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Summary

Filters